Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models

被引：0
作者：
Christian Lehmann
Thomas Friess
Fabian Birzele
Anna Kiialainen
Markus Dangl
机构：
[1] Roche Pharma Research & Early Development,
[2] Roche Innovation Center Munich,undefined
[3] Roche Diagnostics GmbH,undefined
[4] Roche Pharma Research & Early Development,undefined
[5] Roche Innovation Center Basel,undefined
[6] F-Hoffmann-La Roche Ltd,undefined
[7] Present address: Medigene Immunotherapies GmbH,undefined
来源：
Journal of Hematology & Oncology | / 9卷
关键词：
BCL-2; MDM2; AML; Cell cycle kinetics; Apoptosis; Idasanutlin; Venetoclax; p53; MCL-1; Synergism;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models
    Lehmann, Christian
    Friess, Thomas
    Birzele, Fabian
    Kiialainen, Anna
    Dangl, Markus
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2016, 9
  • [2] MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    L Gu
    N Zhu
    H W Findley
    M Zhou
    Leukemia, 2008, 22 : 730 - 739
  • [3] MDM2 antagonist nutlin-3 is a potent inducer of apoptosis in pediatric acute lymphoblastic leukemia cells with wild-type p53 and overexpression of MDM2
    Gu, L.
    Zhu, N.
    Findley, H. W.
    Zhou, M.
    LEUKEMIA, 2008, 22 (04) : 730 - 739
  • [4] Dual Inhibition of MDM2 and XPO1 Induces Synergistic Apoptosis in Wild-type p53 Acute Myeloid Leukemia Through Nuclear Accumulation of p53 and Suppression of c-Myc
    Nishida, Yuki
    Ishizawa, Jo
    Ruvolo, Vivian
    Kojima, Kensuke
    Daver, Naval
    Lesegretain, Arnaud
    Shacham, Sharon
    Andreeff, Michael
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 : S215 - S215
  • [5] Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53
    He, Tianli
    Guo, Jiayou
    Song, Hongmei
    Zhu, Hongcheng
    Di, Xiaoke
    Min, Hua
    Wang, Yuandong
    Chen, Guangzong
    Dai, Wangshu
    Ma, Jianhua
    Sun, Xinchen
    Ma, Jianxin
    PATHOLOGY & ONCOLOGY RESEARCH, 2018, 24 (01) : 75 - 81
  • [6] RNA Sequencing Reveals Candidate Genes and Pathways Associated with Resistance to MDM2 Antagonist Idasanutlin in TP53 Wild-Type Chronic Lymphocytic Leukemia
    Aptullahoglu, Erhan
    Nakjang, Sirintra
    Wallis, Jonathan P.
    Marr, Helen
    Marshall, Scott
    Willmore, Elaine
    Lunec, John
    BIOMEDICINES, 2024, 12 (07)
  • [7] Clinical significance of P53 and Bcl-2 in acute myeloid leukemia patients of Eastern India
    Sahu, Geetaram
    Jena, Rabindra Kumar
    HEMATOLOGY REPORTS, 2011, 3 (03) : 91 - 94
  • [8] A MDM2 inhibitor achieves synergistic cytotoxicity with oncolytic adenoviruses on mesothelioma with the wild-type p53
    Thi Thanh Thao Nguyen
    Zhong, Boya
    Morinaga, Takao
    Kubo, Shuji
    Sekine, Ikuo
    Tada, Yuji
    Tatsumi, Koichiro
    Shimada, Hideaki
    Hiroshima, Kenzo
    Tagawa, Masatoshi
    CANCER SCIENCE, 2018, 109 : 960 - 960
  • [9] Activation of wild-type p53 by MDM2 inhibitors: a new strategy for lymphoma treatment
    Pujals, Anais
    Favre, Loetitia
    Gaulard, Philippe
    Wiels, Joelle
    BLOOD AND LYMPHATIC CANCER-TARGETS AND THERAPY, 2015, 5
  • [10] MDM2 antagonist Nutlin-3a protects wild-type p53 cancer cells from paclitaxel
    SHEN HongChang
    Science Bulletin, 2012, (09) : 1007 - 1012
12345